Targeting homologous recombination, new pre-clinical and clinical therapeutic combinations inhibiting RAD51

Highlights • We have examined the mechanisms of therapy resistance mediated by cancer genome stabilization. • We assess the targeting of RAD51 to overcome resistance, defining it as an effective therapy for cancer treatment. • There are direct and indirect methods to inhibit RAD51 activity via six d...

Full description

Saved in:

Bibliographic Details
Published in:	Cancer treatment reviews Vol. 41; no. 1; pp. 35 - 45
Main Authors:	Ward, Ambber, Khanna, Kum Kum, Wiegmans, Adrian P
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier Ltd 01-01-2015
Subjects:	Combination therapy DNA Damage DNA damage response DNA Repair - genetics Hematology, Oncology and Palliative Medicine Homologous Recombination Humans Molecular Targeted Therapy - methods Neoplasms - drug therapy Neoplasms - genetics RAD51 Rad51 Recombinase - antagonists & inhibitors Synthetic lethality Targeted therapy RAD51 Synthetic lethality Combination therapy Targeted therapy DNA damage response Homologous recombination
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Highlights • We have examined the mechanisms of therapy resistance mediated by cancer genome stabilization. • We assess the targeting of RAD51 to overcome resistance, defining it as an effective therapy for cancer treatment. • There are direct and indirect methods to inhibit RAD51 activity via six different therapeutic mechanisms. • We evaluate the current clinical applications for targeting RAD51 in ovarian, colorectal and malignant gliomas. • RAD51 represents a new clinical target to sensitize tumours to standard therapeutic regimens that induce DNA damage.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1
ISSN:	0305-7372 1532-1967
DOI:	10.1016/j.ctrv.2014.10.006